Bill & Melinda Gates Foundation and Wellcome pledge $300 million to CEPI to fight COVID-19 and combat threat of future pandemics
This news announcement forms part of CEPI’s 100 Days Mission, a campaign delving into how we can compress the vaccine development timeline to 100 days, while also counting down to CEPI’s Global Pandemic Preparedness Summit taking place in March, 2022.

OSLO, Norway; January 19, 2022 –The Coalition for Epidemic Preparedness Innovations (CEPI) this week celebrates its fifth birthday with US$300 million in pledges from the Bill & Melinda Gates Foundation and Wellcome to help fund its work on ending the acute phase of the COVID-19 pandemic and its global plan to take the threat of future pandemics off the table. The two philanthropic foundations were co-founders of CEPI at Davos in 2017, alongside the Governments of Norway and India, and the World Economic Forum.

The financial pledges—which together contribute towards the coalition’s $3.5 billion fundraising target—will help advance CEPI’s efforts to further COVID-19 vaccine R&D through investments in the development of the ‘next generation’ of COVID-19 vaccines, designed to protect against newly emerging variants and for use in low-resource settings.

The funding commitments will also provide critical support to ambitious initiatives set out by CEPI in its six-point pandemic preparedness plan to build a future world that is better prepared for emerging infectious disease outbreaks.

CEPI aims to reduce global epidemic and pandemic risk by preparing for known disease threats through the development of vaccines against its priority pathogens (Chikungunya, Lassa fever, MERS, Nipah, Rift Valley fever) and making them globally accessible. Focussing on Disease X, CEPI’s plan also aims to build on innovations seen in the current pandemic and transform the response to the next novel coronavirus by developing all-in-one coronavirus vaccines designed to protect against multiple SARS-CoV-2 variants and other Betacoronaviruses*. Such tools could take the world beyond the current ‘one bug, one drug’ method and provide broad protection against current and future coronavirus threats.

Dr. Richard Hatchett, Chief Executive Officer, CEPI, said, “The crucial funds that have been pledged set CEPI on a positive trajectory towards our ultimate US$3.5 billion funding goal. Achieving this funding target will enable CEPI to further advance, and enable equitable access to, life-saving vaccines and help the world develop ground-breaking new technologies including universal vaccines against Betacoronaviruses.

“Both these Foundations have shown incredible leadership with regards to global health, and we are enormously grateful to them for their visionary contribution to our work. If fully funded, CEPI’s ambitious plan will revolutionise the way the world deals with future epidemics and could prevent us ever again having to suffer the devastation of a pandemic like COVID-19.

“The future we envisage can only be only realised if the world steps up now to make the investments needed to build on the scientific advances made in response to the COVID-19 pandemic. CEPI calls on political, industry, academic, philanthropic, and civil society leaders to join us and support our bold plan.”…



CEPI and Institut Pasteur de Dakar partner to advance COVID-19 vaccine manufacturing in Africa
DAKAR, Senegal and OSLO, Norway; 18 January 2022: The Coalition for Epidemic Preparedness Innovations (CEPI) and the Institut Pasteur de Dakar (IPD) have signed a Memorandum of Understanding (MoU) to formalize the partnership between the two organizations to advance IPD’s MADIBA project, a regional manufacturing hub for COVID-19 and other vaccines in Dakar, Sénégal. In its initial phase, IPD’s new modular facility will manufacture up to 300 million doses of COVID-19 vaccine annually for use in Africa.

With the manufacturing facility in advanced construction, IPD is on track to start vaccine production in the third quarter of 2022. IPD has previously signed an MOU with BioNTech to pursue mRNA vaccine manufacturing and is actively exploring partnerships with other vaccine companies to produce licensed COVID-19 vaccines in its new manufacturing facility. In the future, IPD plans to expand to produce vaccines against other pathogens that are relevant to the region – potentially also new vaccines funded by CEPI.

CEPI will provide strategic and technical support to IPD’s MADIBA project to advance the development and delivery of vaccines manufacturing in Africa. CEPI will also advise on the implementation of an innovative vaccine filling and delivery solution, licensed from MedInstill/INTACT Solutions and developed with CEPI’s funding and support…